News Breaks |
|
|
| December 28, 2012 |
| 16:13 EDT |  | BMY, PFE | Bristol-Myers, Pfizer win FDA approval for Eliquis
The FDA approved the anti-clotting drug Eliquis, an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured Bristol-Myers Squibb Company (BMY) and marketed by Bristol-Myers Squibb and Pfizer (PFE). Reference Link |
|
|
News For BMY;PFE From The Last 14 Days Check below for free stories on BMY;PFE the last two weeks. |
|
|
| June 19, 2013 |
| 17:52 EDT | | PFE | Pfizer announces final exchange ratio for Zoetis exchange offer
 Subscribe for More Information |
|
| 16:01 EDT |  | PFE | Options Update; June 19, 2013
Subscribe for More Information |
|
| 10:30 EDT |  | PFE | Pfizer management to meet with ISI Group
Subscribe for More Information |
|
| 07:41 EDT |  | PFE | Pfizer holders should consider Zoetis exchange, says BMO Capital
BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. |
|
| 05:43 EDT | | BMY | AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza
Subscribe for More Information |
|
| June 18, 2013 |
| 09:38 EDT | | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM |
|
| June 17, 2013 |
| 16:00 EDT | | PFE | Options Update; June 17, 2013
Subscribe for More Information |
|
| 08:36 EDT | | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. |
|
| 07:28 EDT | | PFE, BMY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information |
|
| June 14, 2013 |
| 16:00 EDT | | PFE | Options Update; June 14, 2013
Subscribe for More Information |
| |
| 09:03 EDT | | BMY | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. |
|
| 08:02 EDT | | BMY | Bristol-Myers, Simcere enter Orencia pact for China
Subscribe for More Information |
|
| 06:45 EDT | | PFE | Zoetis volatility elevated into Pfizer split-off
Subscribe for More Information |
|
| June 13, 2013 |
| 16:00 EDT | | PFE | Options Update; June 13, 2013
Subscribe for More Information |
|
| 11:02 EDT | | BMY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information |
|
| 07:32 EDT | | PFE | European League Against Rheumatism to host annual meeting
Subscribe for More Information |
|
| June 12, 2013 |
| 16:02 EDT | | PFE | Options Update; June 12, 2013
Subscribe for More Information |
|
| 13:31 EDT | | PFE | Mylan could be interested in generic assets split from Pfizer, Bloomberg says
|
|
| 13:15 EDT | | BMY | Bristol-Myers, AstraZeneca issue statement on review of some therapies
Subscribe for More Information |
|
| 08:28 EDT | | PFE | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
Subscribe for More Information |
| |
|
|
|
|
